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Abstract: Classification of lung neuroendocrine (NE) tumors is a 
step-wise process with four tumor categories being identified by 
morphology, namely typical carcinoid (TC), atypical carcinoid, 
large-cell NE carcinoma, and small-cell lung carcinoma (SCLC). 
Ki-67 antigen or protein (henceforth simply Ki-67) has been largely 
studied in these tumors, but the clinical implications are so far not 
clear. A well-defined role has regarded the diagnostic use in the sep-
aration of TC and AC from SCLC in nonsurgical specimens, with 
monoclonal antibody MIB-1 resulting in the most used reagent after 
antigen retrieval procedures. Uncertainties, however, have arisen in 
its assessment, usually expressed as Ki-67 labeling index, because of 
some variability in obtaining either value of the fraction. A diagnos-
tic role is currently lacking, even though there are significant differ-
ences in most cases between TC and AC, less so between large-cell 
NE carcinoma and SCLC. In addition, the prognostic role of Ki-67 
is debated, likely due to methodological and biological reasons. The 
last challenge would be to identify an effective lung-specific grading 
system based on Ki-67 labeling index. In this review article, five rele-
vant issues to Ki-67 have been addressed by using a question-answer 
methodology, with relevant key points discussing major interpreta-
tion issues. The conclusion is that Ki-67 is a feasible and potentially 
meaningful marker in lung NE tumors, but more data are needed to 
determine its ideal function in this setting of tumors.
Key Words: Ki-67, Antigen, MIB-1, Labeling index, Lung, 
Neuroendocrine, Carcinoid, Large-cell neuroendocrine carcinoma, 
Small-cell lung carcinoma, Diagnosis, Immunohistochemistry, 
Prognosis, Therapy.
(J Thorac Oncol. 2014;9: 273–284)
In the lung, neoplasms with neuroendocrine (NE) mor-phology and differentiation encompass four histologically 
defined variants, namely typical carcinoid (TC), atypical 
carcinoid, large-cell NE carcinoma (LCNEC), and small-cell 
carcinoma (SCLC).1,2 According to epidemiologic, genetic, 
and clinical data, pulmonary NE tumors may be assembled 
for prognosis and therapy purposes into a three-tier clinico-
pathological scheme, according to which TC are low-grade 
malignant tumors with long life expectation and usual surgi-
cal treatment; AC, intermediate-grade malignant tumors with 
more aggressive clinical course and multimodality therapy; 
and LCNEC and SCLC, high-grade malignant tumors with 
overlapping dismal prognosis and multimodality or exclusive 
medical treatment.1–8
Subtyping pulmonary NE tumors is a step-wise pro-
cess in which the four histologic variants are primarily sepa-
rated by the number of mitoses per 2 mm2 and the presence 
of necrosis. Immunohistochemistry (IHC) for NE markers 
along with NE morphology is required to separate LCNEC 
from conventional non–small-cell lung carcinoma (NSCLC), 
and the distinction from SCLC is primarily based on cytologi-
cal characteristics, including cell size.1–3,9–11 NSCLC lacking 
NE morphology such as adenocarcinoma or squamous cell 
carcinoma but with NE differentiation by IHC or electron 
microscopy has not been shown consistently to have different 
prognosis or response to treatment, so this is not accepted as a 
distinct class of lung cancer.1,2
Ki-67 antigen, also known as simply Ki-67 or MKI67 
antigen identified by monoclonal antibody Ki-67, is a  359-kD 
non-histone nuclear protein with short half-life, which is 
encoded by the 15 exon-spanning MKI67 gene mapping to 
chromosome 10q26.2. This protein plays an essential role in the 
control and timing of cell proliferation,12–17 which undergoes 
a complex mechanism of post-translational phosphorylation 
and dephosphorylation by cell cycle key regulators leading to 
its subcellular redistribution from the interior of the nucleus/
nucleolus to the perichromosomal layer and heterochromatin 
during mitosis and meiosis and vice versa18–22 Functionally, 
Ki-67 expression is finely tuned by specific microRNAs23 and 
produced during the entire cell cycle with a maximum in the 
G2 and M phases.24,25 However, it may be found at sites linked 
to the ribosomal RNA transcription machinery with a tight 
chromatin-associated function in both interphase and mitotic 
cells, although this finding does not argue against its valuable 
function as proliferation marker.26,27 The name Ki-67 derives 
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from the city of Kiel in Germany where the antibody was first 
raised and the number 67 from the clone position in the origi-
nal 96-well plate generated immunizing mice with nuclei of 
the lymphoma cell line L428.28,29 As the original monoclonal 
antibody to Ki-67 worked on frozen or fresh material only, sub-
sequent antibodies have been developed to react with Ki-67 in 
formalin-fixed and paraffin-embedded material in a huge vari-
ety of malignancies, among which endocrine tumors in dif-
ferent anatomical sites.30 These reagents included polyclonal 
Ki-6731 and monoclonal MIB-1-3-5,32–34 IND.64,35 JG-67-2a,34 
Ki-S1,36 Ki-S3,37 Ki-S5,36,38 and Ki-S1139 antibodies, with 
most studies confirming the validity of results obtained with 
these reagents in the measurement of proliferative activity in 
routinely processed tissues and even cytological samples.40–43 
In more recent years, clone Mib-1 has been emerging as the 
most reliable and consistent reagent to recognize Ki-67 in par-
affin sections32,33 and its wide commercial availability allowed 
many investigative studies and meta-analyses to be performed 
on the clinical implications of Ki-67 to assess proliferative 
activity in different malignancies,44,45 including lung.46
In NE tumor pathology, Ki-67 was first clinically inves-
tigated as prognostic factor in the pancreas,47–49 then exported 
to many other types of intestinal NE tumors50,51 until it was 
incorporated into the grading system of digestive tract NE 
neoplasms in the 2010 world Health Organization (wHO) 
classification.52,53 However, Ki-67 has entered the clinical 
practice of other tumors, such as breast cancer, this outlining 
its role in the molecular classification54 and clinical manage-
ment of these oncologic patients.55 In this evolving scenario 
of increasing clinical appraisal, it is not surprising that Ki-67 
has been widely studied even in NE tumors of the lung.56–72 
However, clarifying its limits and defining practical applica-
tions can help clinicians and pathologists to better understand 
the potential lesson of Ki-67 in the management of NE lung 
tumor patients.
MATERIALS AND METHODS
A general overview of articles thus far published on the 
issue of Ki-67 as an operational IHC marker of cell prolifera-
tion in lung NE tumors is shown in Table 1. The term “NE 
tumor” will be synonymously and interchangeably used with 
the more correct alternative “NE neoplasm” to encompass 
the whole spectrum of lung NE tumors.73 Only articles deal-
ing with the 1999 or 2004 wHO classifications3,4 or equiva-
lent systems58,70 have been considered because they are more 
homogeneous for the definition of NE tumor categories.1,2,4,74 
A list of key questions was developed with regard to techni-
cal issues, diagnostic and prognostic implication, tumor grad-
ing, and relevance to therapy, and these formed the basis for 
the literature review. Our research was limited to the English 
literature available in PubMed by variably crossing differ-
ent research terms, such as Ki-67 or Ki67 (either antigen or 
protein), MIB1, MIB-1, antibody, NE, tumor, neoplasm, pul-
monary, lung, carcinoid, typical, atypical, LCNEC, SCLC, 
prognosis, survival, or therapy. As a whole, 2067 lung NE 
tumors were retrieved corresponding to 25 independent stud-
ies (Table 1). Our work did not intend to perform a quantita-
tive meta-analysis but rather to provide a critical reappraisal 22
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of the literature addressing frequently asked questions on 
NE lung tumor pathology and Ki-67 in daily clinical prac-
tice. Accordingly, a question-answer methodology has been 
pursued in the article, with relevant key points summing up 
major interpretation issues at the end of each answer. In the 
literature, the term hot spot has been used to indicate tumor 
areas with the highest concentration of nuclear decoration for 
Ki-67, whereas the term cold spot has been exploited by some 
studies to indicate the opposite phenomenon of tumor areas 
showing the minimal concentration of Ki-67 immunoreactive 
tumor cells75 (Table 2).
Question 1. Are there relevant technical issues to 
Ki-67 IHC and evaluation of results?
Answer: Yes, there is no uniform methodology for 
Ki-67 IHC and evaluation of results, but most studies pin-
pointed monoclonal antibody MIB-1 on paraffin sections after 
antigen retrieval procedures and the assessment of a Ki-67 
labeling index (LI) as the most widely agreed-upon method-
ologies, which have been optimized within each laboratory by 
longstanding experience on this marker.
Although there are no systematic investigations com-
paring different antibodies against Ki-67 in clinically worked 
up NE lung tumors, clone MIB-1 on paraffin sections has 
been used in all but three articles,57,68,76 with different antibody 
dilutions (ranging from 1:25 to 1:1800) and antigen retrieval 
procedures being adopted within each laboratory usually by 
utilizing heat-induced unmasking systems in saline buffer and/
or following specific manufacturer’s instructions (Table 1). 
Although two articles used prediluted reagents,57,77 five oth-
ers did not provide details on antibody dilutions being 
applied to58,59,61,62,68 and four lacked information about the 
antigen retrieval procedures in use.59,61,67,78 Quantification of 
Ki-67 expression has been accomplished on surgical resec-
tion specimens by manual counting in all but three studies, in 
which automated systems of assessment were exploited.58,68,79 
A high overall agreement of manual Ki-67 LI evaluation and 
an automated evaluation method upon scanned slides have 
recently substantiated the value, reproducibility, and easiness 
of Ki-67 LI upon manual counting.79 Small biopsy and cytol-
ogy samples were used in six57,64,66,76,80,81 and two studies,62,77 
respectively, to witness the applicability of these materials to 
accomplish Ki-67 evaluation. Although two works have imag-
inatively expressed Ki-67 results as either cumulative score81 
or staining index78 by including the intensity of immunore-
activity or the density of stained cells in tumor tissue areas, 
respectively, all the remaining studies used the percentage 
of nuclear-stained tumor cells to substantiate a Ki-67 LI.56–
72,75–77,79,80,82 However, the way to select immunoreactive tumor 
cells differed somewhat among the diverse studies, with six of 
them even not providing useful contributory information for 
further evaluation.57,70,72,77,80,81 Briefly, Ki-67 LI was assessed 
in nine studies pinpointing hot spot63,64,68,69,71,75,78,79,82 or aver-
age labeling frequency fields60 after scanning the entire tumor 
area at low magnification, whereas the quantification of posi-
tive tumor cells per 1 mm2 76 or 2 mm2 58 or randomly selected 
areas61 was declared by others to better accomplish Ki-67 LI. 
In another study, both hot and cold tumor areas were screened, 
in the same tumor samples, at low magnification to count 1000 
tumor nuclei and a separate evaluation was provided for com-
parison.75 Evaluation of stained tumor cells on whole tissue 
sections of biopsy samples has also been used to maximize 
information obtainable from small material and avoid selec-
tion biases.64 No particular details on the selection criteria of 
tumor cells but only the global number of tumor cells being 
assessed were included in other investigations, which did not 
thus contribute to unveiling this issue.56,59,65–67 Interestingly, 
all studies dealing with LI determination were performed on 
biopsy or surgical specimens, except for two cytology investi-
gations that expressed results either by quintiles62 or by Ki-67 
LI.77 All tumor cells showing specific nuclear staining for 
Ki-67 were considered positive regardless of decoration pat-
terns (diffuse, speckled, nucleolar, mitosis featuring), which 
are due to the differential expression of the protein during cell 
cycle progression.24,25 Expectedly, a significant correlation of 
Ki-67 LI with mitotic count59,65,69,75,76,79 or expression of cyclin 
B160 or histone H3 (a surrogate marker of mitoses)75 has been 
described in NE tumors of both the lung and the pancreas48 in 
virtue of the strong colinearity of the two indicators of cycling 
cells with variable correlation coefficients likely due to bio-
logical and technical reasons.75,79
More critical is the question of how Ki-67 LI should 
be calculated, because different methods have been provided 
to establish the optimal denominator, that is, the number of 
cells to be counted. Four to eight histological fields at ×2068 or 
×4069,79 magnification, histological fields with average labeling 
incidence,60 2-mm2 tumor areas taken at ×25 magnification,58 
1-mm2 tumor areas not otherwise specified,76 or 400 to 2000 
tumor cells being consecutively counted56,59–61,63–67,71,75,78,82 
have been used for assessing Ki-67 LI, which may account 
for some discrepant results and preclude a direct cross-study 
comparison.68
Another source of variability may derive from eval-
uating results of Ki-67 LI as mean56,58–61,63–71,75,77,81,82 or 
median57,64,79 thresholds, whereas other studies provided either 
poorly manageable categorical variables76 or no useful infor-
mation.62,72,78,83 Reproducibility studies on Ki-67 LI evaluation 
by repeating the measurements in randomly selected carcinoid 
subsets68 or comparing manual mitotic count with Ki-67 LI by 
different pulmonary pathologists in the same tumor samples79 
revealed encouraging results, with less than 1.5% of variabil-
ity68 and an outperformance of Ki-67 LI over mitotic count 
with regard to interobserver agreement.79
Relevant key points: At variance with the gastroentero-
pancreatic system,84 there are no comparative studies evaluat-
ing different methods to perform and express Ki-67 results 
in lung NE tumors. However, most published investigations 
agreed on the opportunity of measuring Ki-67 LI in hot spot 
areas, taking into account all nuclear signals after visual scru-
tiny of the entire tumor. This would apply especially to TC 
or AC, whereas Ki-67 decoration is usually much more uni-
form in high-grade NE tumors. For practical purposes, Ki-67 
LI should be calculated in surgical specimens by counting at 
least 2000 consecutive tumors cells in hot spot fields at ×40 
magnification or 2 mm2 for consistency with the histological 
classification, possibly in the same tumor area as that used 
for assessing mitotic count. In biopsy or cytology samples, 
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in which the number of tumor cells may be lower than 2000 
and the 2-mm2 criterion unsuitable, it could be reasonable to 
calculate Ki-67 LI on all tumor cells. For experienced pathol-
ogists, manual counting of Ki-67 LI upon visual inspection 
or eyeball estimation differs little from more sophisticated, 
 time-consuming, or cumbersome methods.84 Additional work 
and reproducibility studies are needed to address the optimal 
procedure for evaluating Ki-67 in lung NE tumors.
Question 2. Is there a diagnostic role for Ki-67 LI in 
lung NE tumors?
Answer: No, the classification on NE lung tumors is 
currently guided by morphology alone, but a practical utility 
for this marker has been emerging for separating TC/AC from 
high-grade NE tumors in limited diagnostic material.
As outlined in Table 2, the weighted average of Ki-67 LI 
values across different studies in which this evaluation could 
be done differed between TC and AC but not between LCNEC 
and SCLC when considering both surgical specimens only 
or biopsy/cytology and surgical specimens as a whole, with 
minor differences if hot spot values of Ki-67 LI were taken 
into account. The distribution of Ki-67 LI values across the 
different categories of lung NE tumors according to the type 
of specimens (only excised specimens or excised and biopsy 
samples) and the way to select tumor cells (declared hot spot 
areas versus not declared hot spot areas) is shown in Table 2. In 
three large studies8,64,85 accounting for 628 surgically excised 
NE tumors of the lung (one of which in abstract form only),85 
the value of Ki-67 LI ranged from 2.3% to 4.15% in 211 TC, 
9% to 17.8% in 131 AC, 47.5% to 70.0% in 153 LCNEC, and 
64.5% to 77.5% in 133 SCLC, in substantial agreement with 
the expected proliferation rates of these tumors.
Significant differences in the Ki-67 LI distribution have 
been described in several studies between TC and AC,58–60,64–
66,68,69,71,72,79 between LCNEC and SCLC,64 or across the entire 
spectrum of lung NE tumors,81 whereas other authors did 
not support this correlation at all56,70,75 or limited the failure 
to poorly differentiated NE tumors only.60 Proposed cutoff 
thresholds of Ki-67 LI ranged from 2.5 to approximately 30% 
for carcinoids,58,59,62,64–66,68,69,75,76,79,82 with two studies detecting 
50% or more in few AC,68,70 whereas the separation of SCLC 
and LCNEC, if any,64 is of more limited clinical impact.1,86 
In another study on 190 lung NE tumors published in an 
abstract form only, although there were differences in Ki-67 
LI among diverse tumor categories, the incorporation of this 
marker as a primary criterion in the classification scheme of 
lung NE tumors was not further supported.85 A possible expla-
nation why Ki-67 LI could not effectively split biologically 
adjacent tumor variants could be the imperfect correlation 
with mitotic count. This causes the frequency distributions of 
Ki-67 LI to consistently overlap between these adjacent tumor 
variants,68,69,75 also taking into account the high interobserver 
variability existing, for example, in high-grade NE tumor 
subclassification.87
One of the most agreed-upon uses of Ki-67 LI with 
important clinical implications deals with the distinction 
of low to intermediate grade from poorly differentiated NE 
tumors (especially SCLC) in small biopsy or cytology sam-
ples,57,62,64,71,77 especially in the presence of crush artifacts or 24
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poor tissue preservation,55,60,62 in which nuclear markers are 
more suitable for the diagnostic interpretation than cytoplas-
mic markers. In fact, nuclear markers are easier to scrutiny 
because there is no passive diffusion of cytoplasmic proteins 
into adjacent cells, but chromatin-related molecules, such as 
Ki-67, are likely to remain tightly associated to nuclear rem-
nants even when filamentous changes occur due to tumor cell 
fragmentation. Thresholds up to 25% to 30% of Ki-67 LI 
have been quoted as a useful diagnostic adjunct to exclude 
poorly differentiated NE tumors, which are associated with an 
exceedingly high proliferation index,57,62,64,71 whereas thresh-
olds of less than 3% would support a diagnosis of low-grade 
NE tumor and thresholds between 3% and 30% would indi-
cate indeterminate tumors that most often consisted of AC 
with very few poorly differentiated tumors.75 A comparative 
assessment of Ki-67 LI in biopsy64 or cytology samples77 and 
paired surgical specimens was available from two studies, 
with similar but not perfectly overlapping results in the setting 
of low to intermediate malignant lung NE tumors in keeping 
with those obtained in pancreatic NE tumors,88 likely owing 
to either sampling or methodological issues.64,77 Although it is 
mandatory to avoid major pitfall in the management of lung 
cancer patients and Ki-67 LI assessment is effective to assist 
this task,64 worth noting, however, is that Ki-67 LI on small 
biopsy sample may represent the only available data of cell 
proliferation for clinical decisions in inoperable patients.89
Relevant key points: Ki-67 LI is not part of the current 
wHO diagnostic criteria for classifying lung NE tumors and 
should not be used to differentiate TC and AC owing to consid-
erable overlapping in the distribution of Ki-67 indices between 
biologically adjacent NE tumor categories. The assessment of 
Ki-67 LI, however, is useful as a diagnostic adjunct in small 
biopsy or cytology specimens with poor preservation or crush 
artifact, to avoid misdiagnosing low- to intermediate-grade 
NE tumors as poorly differentiated NE carcinoma.57,62,64,71,77 
Ki-67 LI does not serve to make specific diagnoses of lung 
NE subtypes, rather it very sensitively parallels the inherent 
proliferative properties of the tumors under evaluation.
Question 3: Is there a prognostic role for Ki-67 LI?
Answer: Possibly, Ki-67 LI has been emerging as a 
promising prognostic factor in excised specimens especially 
of low- to intermediate-grade lung NE tumors, although more 
data are needed to establish its ideal role.
As indicated in Table 1, at least 12 articles have investi-
gated the prognostic inference of Ki-67 LI in diverse categories 
of lung NE tumors, especially TC and AC,58–60,63,65,66,68,69,76,78,82,83 
but results are sometimes conflicting and not conclusive yet 
to authorize a well-recognized role as a prognostic factor for 
Ki-67 LI in lung NE tumors. Some authors denied any rel-
evance for this marker to pinpoint differences in patients’ life 
expectancy inside individual tumors categories,60,66,76 whereas 
others indicated a worse prognosis in TC80 or purported a role 
as metastasis predictor alone78 or upon fascin overexpression 
(a protein involved in cell migration).82 Only six studies have 
indeed supported a prognostic role of Ki-67 LI in surgically 
excised TC and/or AC,58,59,65,68,69,80 but results are far from 
being conclusive. In fact, Ki-67 LI seemed to accurately seg-
regate TC and AC into two distinct prognostic categories by 
cutoff values between 2.5% and 5.8%,58,59,65,68,69 which turned 
out independent of morphology in three studies totaling 220 
carcinoids.58,59,65 In another study dealing with 43 TC, patients 
with increased Ki-67 expression had significantly shorter sur-
vival time.80 A note of caution, however, has been advanced 
on the limited role of Ki-67 LI in predicting survival of low 
to intermediate malignant lung NE tumors when lumping TC 
and AC, inasmuch as a threshold of 5% did not offer substan-
tial better survival information over morphology, also within 
individual tumor categories.68 Similar conclusions on the lack 
of an independent prognostic efficacy of Ki-67 LI in lung 
NE tumors have recently been published in an abstract form 
only.85 Interestingly, however, several studies have revealed 
that a Ki-67 LI cutoff of 4% to 5% could differentiate between 
lower and higher malignant NE tumors in the setting of TC 
and AC,58,59,65,68,69,82 similar to what already demonstrated in 
analogous NE tumors of the pancreas.48,49 Although concep-
tually reasonable, no studies have so far addressed a role of 
Ki-67 LI in the prognostic stratification of poorly differenti-
ated NE tumors, at variance with what has been proposed in 
other endocrine organs, such as the pancreas.90
Relevant key points: Ki-67 LI has been proposed as a 
prognostic factor in excised specimens of TC and AC, with 
cutoff values ranging from 2.5% to 5.8%, sometimes but not 
always independent of morphology. The existence of con-
flicting results and the lack of widely agreed-upon cutoff 
thresholds to stratify these tumors preclude making a recom-
mendation at this time. Additional information is needed to 
establish the ideal role of Ki-67 LI in the prognostic assess-
ment of lung NE tumors, ideally helping to predict prognosis 
within individual tumor categories. Because there is not much 
variability in survival for TC, LCNEC, and SCLC, the tumor 
category where there would be the greatest potential to predict 
prognosis is within AC. when lumping TC and AC together, it 
is not surprising that Ki-67 may help with prognosis, but this is 
not really adding anything to existing diagnostic capabilities.
Question 4: Is there an established role for Ki-67 LI 
in tumor grading?
Answer: No, in lung NE tumors, the concept of tumor 
grading as a biological continuum paralleling increasing 
malignancy is tautologically included into the current wHO 
classification, according to which TC are considered low 
malignant, AC intermediate malignant, and LCNEC and 
SCLC high malignant tumors.
In this setting, tumor grade of lung NE tumors refers 
to the degree of biologic aggressiveness and is related to, but 
different from, differentiation that is in turn defined by mor-
phology.73 The main reason why Ki-67 LI assessment cannot 
currently claim any primacy in the grading system of lung 
NE tumors over morphology to realize the clinical three-tier 
spectrum regards its suboptimal correlation with histological 
features used for classification, especially mitotic count75,79 
and necrosis, which causes adjacent categories of tradition-
ally assessed tumors to partially imbricate with each other. 
This also reflects the fact that morphology itself is insufficient 
in separating borderline/overlapping lesions for either low to 
intermediate malignant or high malignant tumors.3,7,91 To try 
to overcome the drawback of the largely expected close but 
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not perfect colinearity of Ki-67 and mitotic count, the grading 
system devised for digestive NE tumors (G1: <2 mitoses per 
2 mm2 and/or Ki-67 LI ≤2%; G2: 2–20 mitoses per 2 mm2 and/
or Ki-67 LI >2% but ≤20%; G3: >20 mitoses per 2 mm2 and 
Ki-67 LI >20%)52,92 has been tested on 111 TC and 83 AC to 
identify tumor subpopulations from lower to higher aggres-
sive biological behavior.69 All TC corresponded to G1 tumors 
using the mean (1.8%) but not hot spot (2.5%) values of Ki-67 
LI, whereas all AC resulted in G2 tumors by either threshold 
(3.7% and 5.8%, respectively). Distribution of tumors across 
this scheme indicated that 72.3% more patients with G2 tumors 
(no tumor fit with G3 criteria) developed lymph node metasta-
ses, 18.2% more distant metastases, and 20% more died, when 
compared with traditionally assessed AC, thereby concluding 
that Ki-67 LI in addition to mitotic count could improve the 
prediction of clinical behavior of lung carcinoids.69 This work, 
however, was not supported by multivariate analysis to vali-
date superiority of this grading system in lung NE tumors in 
comparison with the traditional criteria adopted in wHO 2004 
classification, and in this data set, the method used to apply 
the 2004 wHO criteria resulted in an extraordinary finding 
of significantly greater lymph node metastases in TC (25.2%) 
compared with AC (13.4%).1 Other works have correlated the 
distribution of Ki-67 LI with tumor grade according to the 
usual diagnostic categories by light microscope,75,77 but they 
reflected variations in tumor cell differentiation along the clin-
icopathologic spectrum of lung NE tumors rather than intro-
ducing a grading system based on Ki-67 LI.
Relevant key points: Establishing a lung-specific grad-
ing system based on a widely agreed-upon marker, such as 
Ki-67 LI, alone or better in combination with other morpho-
logic parameters, in analogy with other NE tumors elsewhere 
in the body, is a desirable and clinically warranted goal, also 
because this marker is familiar to most oncologists and pathol-
ogists. However, to date, the existing data do not support a rec-
ommendation to apply to the lung the grading systems devised 
for NE tumors in other anatomical sites, particularly the gas-
trointestinal tract. Nonetheless, the behavioral heterogeneities 
within individual lung NE tumor subtypes (especially AC and 
LCNEC) may be opportunities in future research to develop 
a specifically devised grading procedure for lung NE tumors 
where Ki-67 LI as defined by widely agreed-upon criteria 
according to a grading system could play a role even within 
individual tumor categories.
Question 5: Is there a predictive role for Ki-67 LI in 
therapeutic decisions?
Answer: No, the therapy of NE lung tumors is basically 
guided by morphology and tumor staging by tumor, node, 
metastasis (TNM) system, with TC being usually treated by 
surgery, AC, and LCNEC by multimodality approach espe-
cially in advanced stage and SCLC by almost exclusive 
chemoradiotherapy.5
The role of Ki-67 LI may be directed to improve diag-
nosis for better chance of cure, especially in challenging 
cases of small biopsy or cytology specimens,64 but its direct 
implications in establishing the type, timing, and results of 
therapy have not been evaluated by randomized trials, but 
at the moment, a role as dynamic biomarker of treatment 
efficacy has not been provided. A correlation between exci-
sion repair cross-complementation 1 expression, a resistance 
factor against platinum-based chemotherapy in lung cancer, 
and Ki-67 LI has been described in diverse lung NE tumors 
considered as a whole, although the correlation was weak and 
the significance disappeared within different tumor types.66
Another study investigated the relationship between 
Ki-67 LI and thymidylate synthase expression, an enzyme 
involved in DNA synthesis whose expression acts as a resis-
tance factor to fluoropyrimidine therapy, but results showed 
that these two markers were independently regulated.93 
Likewise, the expression of mammalian target of rapamycin 
signaling activation pathways, an attractive target for mam-
malian target of rapamycin inhibitors such as everolimus in 
NE tumors, did not correlate with Ki-67 LI.8 In conventional 
NSCLC, the predictive impact of Ki-67 to treatment has 
remained unclear.94
Relevant key points: There are no randomized trials 
documenting that establishing Ki-67 LI in lung NE tumors 
may guide therapy, beyond refining better diagnosis in difficult 
cases, usually with small crushed biopsy specimens. Future 
work will determine the role of evaluating Ki-67 in lung NE 
tumors other than SCLC (most often are AC and LCNEC, the 
less familiar categories of these tumors), for deciding chemo-
therapy intervention especially in symptomatic patients with 
clinically aggressive tumors.
CONCLUSIONS AND PERSPECTIVES
Three decades after its introduction in the medicine 
practice and 20 years after its proven prognostic relevance 
for pancreatic and digestive NE tumors, Ki-67 continues to 
be a protagonist marker also in lung NE tumors. Conflicting 
results may be stemming from several factors, including 
selection of patients, number and type of tumors under 
evaluation, histological criteria used for classification, vari-
ability in the choice of antibodies and immunostaining pro-
tocols, Ki-67 staining cutoff thresholds, assessment criteria 
(automated analysis, manual counting, eyeball estimation, 
field and cell selection, number of analyzed cells), length 
and accuracy of  follow-up, and/or clinical parameters under 
evaluation, which may have prevented direct cross-study 
comparisons. Establishing a lung-specific and clinically 
meaningful grading system based on Ki-67 LI, alone or 
in combination with other parameters, with defined cutoff 
thresholds and uniform procedures for assessing Ki-67 LI is 
clinically warranted.
KEY REMARKS
◆	 The most agreed-upon procedure to express  Ki-67 is to 
calculate the percentage of stained tumor cells on at least 
2000 cells in hot spot areas (Ki-67 labeling index).
◆	 Lung NE tumors are classified by morphology, and Ki-67 
does not provide relevant information because of over-
lapping values in biologically adjacent tumor categories.
◆	 Ki-67 LI is useful to avoid misdiagnosing TC and AC as 
SCLC.
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◆	 Avoid untested and untrusting grading systems devised 
for NE tumors of other anatomical sites because of the 
expected different biology.
◆	  Ki-67 LI correlates closely but not perfectly with mitotic 
count introducing more ample information on NE tumor 
cell population: a more sensitive grading system should 
hopefully include both parameters.
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